Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (8052)	10/16/2006 10:30:40 AM
From: LOR	Read Replies (1) \| Respond to of 8117

10% Hailed by PYNG as REAL PROGRESS(ugh) Hi again Ed, Well at least we can say thet PYNG keeps on "chuggin along". Of course, by now they should be up or past 10 times that annual sales volume if their Chief Flounder's past projections were any indication. Do you have ANY idea of what their current maximum production volume of FAST-1's could be based on current manufacturing locations? Best regards, Lor ********************************************************* "Pyng Medical records sales of $3-million in 2006 Pyng Medical Corp (2) (C:PYT) Shares Issued 13,651,583 Last Close 10/13/2006 $0.28 Monday October 16 2006 - News Release Mr. Kevin O'Neill reports PYNG MEDICAL CONTINUED SUCCESS ON REVENUE GROWTH AND DIVERSIFICATION STRATEGY Pyng Medical Corp. has recorded fiscal year 2006 sales of $3,088,448 (fiscal year 2005 $2,797,744), a 10-per-cent sales increase. Fourth quarter sales were $979,300 (fiscal year 2005 $840,328), an increase of 17 per cent. Fourth quarter and third quarter sales were stronger and showed a marked increased over the previous two quarters and the same periods last fiscal. The company has sold and shipped its 75,000th unit of F.A.S.T.1 in September, 2006. As has been the case with all Canadian corporations dealing in the United States, changes to the exchange rates compared with fiscal year 2005 depressed Pyng revenues. The actual increase in revenue experienced was due to a significant increase in F.A.S.T.1 unit sales of 15-per-cent offsetting the decline in the United States dollar exchange. Also of significance was the increase in the sales of training systems, 30 per cent for some distributors, boding well for future system sales. Pyng Medical continues to be profitable with strong cash position in spite of these exchange rate issues. All of the recently newly appointed distributors have started to make a contribution to revenue, particularly in the fourth quarter, as the sales activities yield results. The appointment was to address the opportunities created by the changes to the ILCOR guidelines. These changes have created increased opportunities for the F.A.S.T.1, particularly in the civilian market to address medical conditions such as cardiac arrests. The American Heart Association estimates that Emergency Medical Services (EMS) treats 107,000 to 240,000 cardiac arrests in the United States annually, a significant opportunity for Pyng's F.A.S.T.1. Sales in Europe also increased, particularly in Germany and the United Kingdom. These increases resulted from both the military and civilian sectors. Increased European sales are part of Pyng's sales diversification strategy and to avoid future dependence on the exchange rate. Pyng Medical staff will attend Medica in November, 2006, one of Europe's premier medical shows. The primary purpose of this attendance is to appoint additional distributors in European and other key global markets. © 2006 Canjex Publishing Ltd"